Ernexa Therapeutics
ERNA
3 hedge funds and large institutions have $1.84M invested in Ernexa Therapeutics in 2013 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0.16% less ownership
Funds ownership: 7.43% → 7.26% (-0.16%)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $12K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$12K |
ERNA Hedge Fund Activity: Q3 2013 in Review
3 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Ernexa Therapeutics (ERNA) for Q3 2013, worth a combined $1.84M — down 15% from $2.18M a quarter earlier.
Fund positioning in ERNA was balanced in Q3 2013: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Citadel Advisors, cutting an estimated $12K.
- 3 institutional investors held Ernexa Therapeutics (ERNA) as of Q3 2013, unchanged from Q2 2013.
- Funds reported $1.84M of Ernexa Therapeutics stock for Q3 2013, down 15% quarter-over-quarter.
- 0 funds opened new Ernexa Therapeutics positions in Q3 2013 and 0 closed out.
- The largest Ernexa Therapeutics seller in Q3 2013 was Citadel Advisors, an estimated $12K sold.
Based on aggregated 13F filings for Q3 2013.